Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer-Reference-Cited by-同舟云学术

Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer

Published:2010-11 Issue:11 Volume:10 Page:1825-1836
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Mouridsen Henning T,Lønning Per,Beckmann Matthias W,Blackwell Kimberly,Doughty Julie,Gligorov Joseph,Llombart-Cussac Antonio,Robidoux Andre,Thürlimann Beat,Gnant Michael

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

http://www.tandfonline.com/doi/pdf/10.1586/era.10.160

Reference84 articles.

1. Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer

2. Use of tamoxifen for breast cancer: twenty-eight years later.

3. Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors

4. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?

5. Antiaromatase Agents: Preclinical Data and Neoadjuvant Therapy

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of geriatric characteristics and comorbidities on distant metastases and other cause mortality in older women with non-metastatic breast cancer treated with primary endocrine therapy;Breast Cancer Research and Treatment;2023-07-21

2. Carbon nanospheres conjugated bisphosphonates: synthesis, characterization and in vitro antimalarial activity;Artificial Cells, Nanomedicine, and Biotechnology;2018-11-12

3. Pathways to Breast Cancer Recurrence;ISRN Oncology;2013-02-28

4. Obesity, Type 2 Diabetes and Cancer;Insulin-like Growth Factors and Cancer;2011-08-10